Clinical Trials · NCT03013543

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Name: Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Setmelanotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 213
Start date: Feb 2017
Locations: 58 sites, 9 countries
Primary endpoint: Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment

View Setmelanotide compound reference